Abstract
Summary
Europe PCR based transplant diagnostics market is expected to reach USD 240,123.15 thousand by 2031, from USD 151,409.28 thousand in 2023 growing at the CAGR of 6.2% in the forecast period of 2024 to 2031.
Market Segmentation
Europe PCR based Transplant Diagnostics Market, By Test Type (CMV PCR Test, EBV PCR Test, BKV PCR Test, VZV PCR Test, HSV1 PCR TestHSV2 PCR Test, Parvovirus B19 PCR Test, P. Jirovecii PCR Test, JCV PCR Test, Adenovirus PCR Test, and Aspergillus Spp PCR Test), By Transplant Type (Kidney Transplantation, Liver Transplantation, Heart Transplantation, Lung Transplantation, Pancreas Transplantation, and Other Transplantations), Application (Diagnostic Applications and Research Applications), End User (Hospitals and Transplant Centers, Commercial Service Providers, Research Laboratories and Academic Institutes), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of the Europe)– Industry Trends and Forecast to 2031
Overview of Europe PCR Based Transplant Diagnostics Market Dynamics
Driver
• Increasing prevalence of organ failure
Restraint
• Shortage of professionals with expertise in transplant diagnostics
Opportunity
• Strategic initiation and technology launches by market players
Market Players
Some of the major market players in Europe PCR based transplant diagnostics market are:
• Quest Diagnostics Incorporated.
• Eurofins Viracor, LLC
Table of Contents
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 OVERVIEW OF THE EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET 14
1.4 CURRENCY AND PRICING 15
1.5 LIMITATIONS 15
1.6 MARKETS COVERED 16
2 MARKET SEGMENTATION 18
2.1 MARKETS COVERED 18
2.2 GEOGRAPHICAL SCOPE 19
2.3 YEARS CONSIDERED FOR THE STUDY 20
2.4 DBMR TRIPOD DATA VALIDATION MODEL 21
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 24
2.6 MULTIVARIATE MODELLING 25
2.7 TEST TYPE SEGMENT LIFELINE CURVE 25
2.8 MARKET END USER COVERAGE GRID 26
2.9 DBMR MARKET POSITION GRID 27
2.10 VENDOR SHARE ANALYSIS 28
2.11 SECONDARY SOURCES 29
2.12 ASSUMPTIONS 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 32
4.1 PESTAL ANALYSIS 33
4.2 PORTERS FIVE FORCES 34
5 MARKET OVERVIEW 35
5.1 DRIVERS 37
5.1.1 INCREASING PREVALENCE OF ORGAN FAILURE 37
5.1.2 RISING POPULARITY OF NON-INVASIVE DIAGNOSTIC METHODS 37
5.1.3 ADVANCEMENT IN ORGAN PRESERVATIVE TECHNIQUES 38
5.1.4 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES 39
5.2 RESTRAINTS 40
5.2.1 SHORTAGE OF PROFESSIONALS WITH EXPERTISE IN TRANSPLANT DIAGNOSTICS 40
5.2.2 HIGH COST OF PCR/NGS SOFTWARE 40
5.3 OPPORTUNITIES 41
5.3.1 STRATEGIC INITIATION AND TECHNOLOGY LAUNCHES BY MARKET PLAYERS 41
5.3.2 RISE IN GOVERNMENT SUPPORT AND FUNDING FOR PCR-BASED ORGAN TRANSPLANTATION 41
5.3.3 SURGE OF AWARENESS FOR ORGAN TRANSPLANTATION 42
5.4 CHALLENGES 43
5.4.1 ETHICAL CHALLENGES FACED DURING ORGAN TRANSPLANTATION 43
5.4.2 LACK OF ORGAN DONORS AND PROVIDERS ANNUALLY 44
6 EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TEST TYPE 45
6.1 OVERVIEW 46
6.2 CMV PCR TEST 50
6.3 EBV PCR TEST 50
6.4 BKV PCR TEST 50
6.5 VZV PCR TEST 51
6.6 HSV1 PCR TEST 52
6.7 HSV2 PCR TEST 52
6.8 PARVOVIRUS B19 PCR TEST 52
6.9 P. JIROVECII PCR TEST 53
6.10 JCV PCR TEST 54
6.11 ADENOVIRUS PCR TEST 54
6.12 ASPERGILLUS SPP PCR TEST 55
7 EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE 56
7.1 OVERVIEW 57
7.2 KIDNEY TRANSPLANTATION 60
7.3 LIVER TRANSPLANTATION 61
7.4 HEART TRANSPLANTATION 61
7.5 LUNG TRANSPLANTATION 62
7.6 PANCREAS TRANSPLANTATION 62
7.7 OTHER TRANSPLANTATIONS 63
8 EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 64
8.1 OVERVIEW 65
8.2 DIAGNOSTIC APPLICATIONS 68
8.3 RESEARCH APPLICATIONS 69
9 EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY END USER 70
9.1 OVERVIEW 71
9.2 HOSPITALS AND TRANSPLANT CENTERS 74
9.3 COMMERCIAL SERVICE PROVIDERS 75
9.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES 75
10 EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY 76
10.1 EUROPE 78
10.1.1 FRANCE 81
10.1.2 U.K 83
10.1.3 SPAIN 85
10.1.4 GERMANY 87
10.1.5 TURKEY 89
10.1.6 ITALY 91
10.1.7 RUSSIA 93
10.1.8 NETHERLANDS 95
10.1.9 BELGIUM 97
10.1.10 SWITZERLAND 99
10.1.11 REST OF EUROPE 101
11 EUROPE PCR BASED TRANSPLANT DIAGNOSTICS MARKET, COMPANY LANDSCAPE 102
11.1 COMPANY SHARE ANALYSIS: EUROPE 102
12 SWOT ANALYSIS 103
13 COMPANY PROFILES 104
13.1 QUEST DIAGNOSTICS INCORPORATED 104
13.1.1 COMPANY SNAPSHOT 104
13.1.2 REVENUE ANALYSIS 104
13.1.3 COMPANY SHARE ANALYSIS 105
13.1.4 PRODUCT PORTFOLIO 105
13.1.5 RECENT DEVELOPMENTS 106
13.2 LABORATORY CORPORATION OF AMERICA HOLDINGS 107
13.2.1 COMPANY SNAPSHOT 107
13.2.2 REVENUE ANALYSIS 107
13.2.3 COMPANY SHARE ANALYSIS 108
13.2.4 PRODUCT PORTFOLIO 108
13.2.5 RECENT DEVELOPMENT 109
13.3 EUROFINS VIRACOR 110
13.3.1 COMPANY SNAPSHOT 110
13.3.2 COMPANY SHARE ANALYSIS 110
13.3.3 PRODUCT PORTFOLIO 111
13.3.4 RECENT DEVELOPMENTS 112
13.4 SONIC HEALTHCARE LIMITED 113
13.4.1 COMPANY SNAPSHOT 113
13.4.2 PRODUCT REVENUE ANALYSIS 113
13.4.3 COMPANY SHARE ANALYSIS 114
13.4.4 PRODUCT PORTFOLIO 114
13.4.5 RECENT DEVELOPMENTS 115
13.5 DR LAL PATHLABS 116
13.5.1 COMPANY SNAPSHOT 116
13.5.2 REVENUE ANALYSIS 116
13.5.3 COMPANY SHARE ANALYSIS 117
13.5.4 PRODUCT PORTFOLIO 117
13.5.5 RECENT DEVELOPMENTS 118
13.6 ARUP LABORATORIES 119
13.6.1 COMPANY SNAPSHOT 119
13.6.2 PRODUCT PORTFOLIO 119
13.6.3 RECENT DEVELOPMENT 119
13.7 AMBAR LAB 120
13.7.1 COMPANY SNAPSHOT 120
13.7.2 PRODUCT PORTFOLIO 120
13.7.3 RECENT DEVELOPMENTS 120
14 QUESTIONNAIRE 121
15 RELATED REPORTS 124